credits/contact hours

Learn From the Experts About
Clinical Advances and Case Studies in Immune Checkpoint Inhibitors in Oncology

Learn about the immune system and immune checkpoint targets, as well as everything the oncology AP needs to know about managing immune-related adverse events. 



Upon completion of this activity, participants will be able to:

  • Differentiate between early and late adverse effects associated with immunotherapeutic agents.
  • Recognize the differences between the immunotherapeutic agents and of chemotherapeutic agents: mechanisms of action, adverse effects, and toxicity management.
  • Summarize data on currently available immunotherapeutic agents as they relate to durable treatment responses.
  • Explain the utility of biomarker testing in selecting patients for immunotherapy and in predicting clinical outcomes.